Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC)
targeting folate receptor alpha (FRα) and is indicated for the treatment of adult patients with …

Emerging monoclonal antibody therapies are assuming greater importance in the
management of severe and refractory forms of immunity-driven and oncological disorders …

Background New targeted antibody–drug conjugates (ADCs) against multiple myeloma are
known to induce adverse effects that may lead to treatment discontinuation. Preclinical …

The corneal epithelium (CE) is the outermost layer of the cornea with constant turnover,
relative stability, remarkable plasticity, and compensatory properties to mask alterations in …

Antibody-drug conjugates (ADCs) are a growing class of chemotherapeutic agents for the
purpose of treating cancers that often have relapsed or failed first-and second-line …

Abstract Purpose of Review This study is to highlight the incidence of corneal
pseudomicrocysts in FDA-approved antibody–drug conjugates (ADCs), and success of …

Belantamab mafodotin (belamaf) is a novel antibody–drug conjugate developed for the
treatment of patients with relapsed or refractory multiple myeloma (RRMM). Although the …

Introduction Multiple new drugs have been approved over the past 5 years for the treatment
of relapsed/refractory multiple myeloma (RRMM), and these are being increasingly widely …

Background: Belantamab mafodotin (belamaf) has demonstrated clinically meaningful
antimyeloma activity in patients with heavily pretreated multiple myeloma. However, it is …

The corneal epithelium (CE) is the outermost layer of the cornea with constant turnover,
relative stability, remarkable plasticity, and compensatory properties to mask alterations in …